Central Bank & Trust Co. lowered its position in Danaher Co. (NYSE:DHR) by 24.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,022 shares of the conglomerate’s stock after selling 665 shares during the quarter. Central Bank & Trust Co.’s holdings in Danaher were worth $188,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently modified their holdings of the company. GQG Partners LLC acquired a new position in shares of Danaher during the second quarter worth about $101,000. Zions Bancorporation lifted its stake in shares of Danaher by 118.3% during the third quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock worth $106,000 after purchasing an additional 667 shares in the last quarter. Patten Group Inc. lifted its stake in shares of Danaher by 262.3% during the third quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock worth $114,000 after purchasing an additional 3,497 shares in the last quarter. Monetary Management Group Inc. lifted its stake in shares of Danaher by 10.7% during the second quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock worth $131,000 after purchasing an additional 150 shares in the last quarter. Finally, Acrospire Investment Management LLC lifted its stake in shares of Danaher by 185.5% during the second quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock worth $143,000 after purchasing an additional 1,100 shares in the last quarter. Hedge funds and other institutional investors own 76.11% of the company’s stock.

Several research analysts recently commented on the company. Robert W. Baird reiterated a “buy” rating on shares of Danaher in a research note on Friday, January 12th. Royal Bank of Canada reiterated a “hold” rating and issued a $96.00 price target on shares of Danaher in a research note on Thursday, January 4th. Evercore ISI assumed coverage on Danaher in a research note on Wednesday, January 3rd. They issued an “outperform” rating on the stock. Zacks Investment Research cut Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, December 19th. Finally, Credit Suisse Group reiterated a “hold” rating and issued a $99.00 price target on shares of Danaher in a research note on Tuesday, December 19th. One analyst has rated the stock with a sell rating, six have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Danaher has an average rating of “Buy” and an average price target of $94.91.

In other news, CAO Robert S. Lutz sold 11,189 shares of the company’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $91.66, for a total transaction of $1,025,583.74. Following the completion of the transaction, the chief accounting officer now directly owns 18,314 shares of the company’s stock, valued at $1,678,661.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Donald J. Ehrlich sold 10,578 shares of the company’s stock in a transaction that occurred on Tuesday, October 24th. The shares were sold at an average price of $90.82, for a total value of $960,693.96. Following the transaction, the director now directly owns 104,621 shares of the company’s stock, valued at $9,501,679.22. The disclosure for this sale can be found here. Over the last three months, insiders sold 273,810 shares of company stock valued at $25,218,813. 12.20% of the stock is owned by corporate insiders.

Shares of Danaher Co. (NYSE DHR) opened at $99.47 on Wednesday. The company has a quick ratio of 1.00, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $69,136.20, a PE ratio of 29.34, a P/E/G ratio of 2.15 and a beta of 1.02. Danaher Co. has a fifty-two week low of $78.97 and a fifty-two week high of $100.27.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.95 by $0.05. The firm had revenue of $4.53 billion during the quarter, compared to analyst estimates of $4.47 billion. Danaher had a return on equity of 11.29% and a net margin of 13.36%. Danaher’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.87 earnings per share. equities analysts anticipate that Danaher Co. will post 3.99 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be issued a $0.14 dividend. This represents a $0.56 annualized dividend and a yield of 0.56%. The ex-dividend date of this dividend is Thursday, December 28th. Danaher’s dividend payout ratio is currently 16.52%.

ILLEGAL ACTIVITY WARNING: “Danaher Co. (DHR) Shares Sold by Central Bank & Trust Co.” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/danaher-co-dhr-shares-sold-by-central-bank-trust-co/1810217.html.

Danaher Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.